Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Study finds increased risk of liver injury with some TB medications


A newly recommended treatment for latent tuberculosis (TB) infection can cause liver injury, and therefore needs to be used with great caution and frequent monitoring, according to a UCSF-led, multi-center study.

The research reporting the increased liver injury from the drugs, rifampin and pyrazinamide, was conducted by investigators at UCSF, Boston University, and Emory University and appears in the October 15 issue of the Annals of Internal Medicine.

The study is the first large-scale clinical trial to compare the newly recommended and shorter duration treatment – two months of rifampin and pyrazinamide -- with the standard treatment, six months of isoniazid, to treat patients with latent TB infection.

"We found that patients taking the two-drug treatment had a much higher rate of major liver injury than those who took the standard treatment of isoniazid," said principal investigator Robert M. Jasmer, MD, UCSF assistant professor of medicine, who treats patients in the division of tuberculosis control at San Francisco General Hospital Medical Center (SFGHMC).

Caused by the organism Mycobacterium tuberculosis, TB is a chronic bacterial infection that usually causes disease in the lungs but also attacks other organs. TB is usually dormant (or latent) in the body for years, but around ten percent of latently infected individuals will develop active TB at some time in their lives. It is estimated that 10-15 million people in the U.S. and 2 billion people in the world are infected with TB bacteria. People who have been recently infected or have a condition that increases their chances of developing active TB are recommended to undergo treatment for latent TB infection to prevent them from developing active TB in the future, said Jasmer.

Study findings showed that eight percent of patients taking the rifampin and pyrazinamide regimen developed significant liver injury compared with only one percent of those taking isoniazid. Other side effects and the percentage completing treatment were similar between the two groups.

Previous studies had shown that the two-drug treatment was safe and effective in HIV-infected persons with latent TB infection, so experts recommended this treatment as a new option for all adults in the U.S. in 2000, explained Jasmer. However, the Centers for Disease Control and Prevention (CDC) received reports of eight deaths due to liver failure among patients treated with the two-drug regimen. These deaths led to new recommendations to monitor patients closely every two weeks who are prescribed the rifampin and pyrazinamide treatment.

In the study, known as the SCRIPT (Short-Course Rifampin and Pyrazinamide for TB Infection) Study, 589 patients were enrolled and assigned to treatment with either the rifampin and pyrazinamide regimen or isoniazid. All patients underwent frequent monitoring for side effects and blood tests to detect liver damage. No patients in the study were hospitalized for liver disease, and all had complete resolution of their liver abnormalities after discontinuation of the medications when necessary.

"Our study confirms the new CDC recommendations for frequent monitoring of patients treated with the two-drug regimen so that they are evaluated every two weeks, including testing their blood for markers of liver injury. The vast majority of patients did fine and completed the treatment without major side effects, but laboratory monitoring is essential to detect those with early liver injury and prevent progression to severe toxicity," Jasmer said.

Maureen McInaney | EurekAlert!

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Greater Range and Longer Lifetime

26.10.2016 | Power and Electrical Engineering

VDI presents International Bionic Award of the Schauenburg Foundation

26.10.2016 | Awards Funding

3-D-printed magnets

26.10.2016 | Power and Electrical Engineering

More VideoLinks >>>